



Does the Type of Hysterectomy Affect the Survival of Patients with Clinical IA Endometrial Cancer: A Multicenter Retrospective Study

Chenmian Liu, Kun Song, Ran Chu
Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China

Objective

- To evaluate the clinical prognosis of different types of hysterectomy for the treatment of patients with clinical stage IA endometrial cancer.

Materials and methods

- The study included 1157 patients with clinical IA EC who underwent hysterectomy. 1:1 propensity-score matching(PSM) was performed between type A hysterectomy (simple total hysterectomy) and type B/C hysterectomy (modified or radical hysterectomy). Disease-free survival (DFS) and overall survival (OS) were assessed using Kaplan–Meier curves. Cox proportional hazards regression analysis was used to analyze the risk factors for DFS.

Results

- A total of 960 (92.6%) patients underwent type A hysterectomy and 97 (9.4%) underwent type B/C hysterectomy. Patients in the type B/C group showed worse surgical details, included greater estimated blood loss (median 200 vs. 120 mL, $P < 0.001$), longer postoperative hospital stays (median 19 vs. 11 days, $P < 0.001$), and more postoperative complications (6.2% vs. 2.0%, $P = 0.009$). The two groups showed no significant differences in DFS and OS before and after matching ($P > 0.05$). Multivariate Cox analysis revealed that cervical involvement and lymph node metastasis were prognostic factors for survival.

Conclusions

- Radical or modified radical hysterectomy did not affect the clinical prognosis of patients with clinical stage IA endometrial carcinoma. However, these procedures could result in worse surgical details, like greater blood loss, more postoperative complications, and longer hospital stays. The choice of radical hysterectomy needs to be carefully considered in clinical practice.

E-mail address: mxh181102@163.com

Figure1: The workflow of this study




Figure2: Survival outcome before and after PSM




Figure 1. The workflow of this study

Characteristics	Before PSM				After PSM			
	Total (n=1057)	Type A (n=960)	Type B/C (n=97)	P	Total (n=188)	Type A (n=94)	Type B/C (n=94)	P
Age (year)				0.202				0.365
<60	567 (53.6)	509 (53.0)	58 (59.8)		118 (62.8)	62 (66.0)	56 (59.6)	
≥60	490 (46.4)	451 (47.0)	39 (40.2)		70 (37.2)	32 (34.0)	38 (40.4)	
BMI (kg/m ²)				0.378				0.581
<24	127 (12.0)	117 (12.2)	10 (10.3)		18 (9.6)	8 (8.5)	10 (10.6)	
≥24	211 (20.0)	196 (20.4)	15 (15.5)		26 (13.8)	11 (11.7)	15 (16.0)	
Unknown	719 (68.0)	647 (67.4)	72 (74.2)		144 (76.6)	75 (79.8)	69 (73.4)	
CA-125 (U/mL)				0.059				0.762
≤35	589 (55.7)	546 (56.9)	43 (44.3)		91 (48.4)	48 (51.1)	43 (45.7)	
>35	126 (11.9)	111 (11.6)	15 (15.5)		29 (15.4)	14 (14.9)	15 (16.0)	
Unknown	342 (32.4)	303 (31.6)	39 (40.2)		68 (36.2)	32 (34.0)	36 (38.3)	
Comorbidities				0.525				0.883
Hypertension	501 (47.4)	458 (47.7)	43 (55.7)		85 (45.2)	43 (45.7)	42 (44.7)	
Diabetes	342 (32.4)	317 (33.0)	25 (25.8)	0.146	47 (25.0)	22 (23.4)	25 (26.6)	0.613
Cardiovascular disease	127 (12.0)	114 (11.9)	13 (13.4)	0.659	27 (14.4)	14 (14.9)	13 (13.8)	0.835
Surgical route				0.109				0.824
Laparotomy	86 (8.1)	74 (7.7)	12 (12.4)		23 (12.2)	12 (12.8)	11 (11.7)	0.613
Laparoscopy/robotic	592 (56.0)	517 (53.9)	75 (77.3)	<0.001	141 (75.0)	69 (73.4)	72 (76.6)	
Lymphadenectomy	456 (44.0)	2443 (46.1)	22 (22.7)	<0.001	47 (25.0)	25 (26.6)	22 (23.4)	1.000
No	456 (43.1)	432 (45.0)	24 (24.7)		48 (25.5)	24 (25.5)	24 (25.5)	
Yes	601 (56.9)	528 (55.0)	73 (75.3)		140 (74.5)	70 (74.5)	70 (74.5)	
Omentectomy				0.001				1.000
No	981 (92.8)	899 (93.6)	82 (84.5)		164 (87.2)	82 (87.2)	82 (87.2)	
Yes	76 (7.2)	61 (6.4)	15 (15.5)		24 (12.8)	12 (12.8)	12 (12.8)	

Table2. Surgical details of two groups of patients

Surgical details	Before PSM				After PSM			
	Total (n=1057)	Type A (n=960)	Type B/C (n=97)	P	Total (n=188)	Type A (n=94)	Type B/C (n=94)	P
Operative time (minute)	150 (45-360)	150 (45-360)	145 (65-300)	0.194	145 (60-315)	140 (60-315)	150 (65-300)	<0.001
Estimated blood loss (mL)	150 (10-1500)	120 (10-1500)	200 (20-1500)	<0.001	200 (20-1500)	200 (50-800)	200 (20-1500)	0.027
Transfusion				<0.001				0.004
No	1003 (94.4)	924 (96.3)	79 (81.4)		165 (87.8)	89 (94.7)	76 (80.9)	
Yes	54 (5.1)	36 (3.8)	18 (18.6)		23 (12.2)	5 (5.3)	18 (19.1)	
Postoperative complications	25 (2.4)	19 (2.0)	6 (6.2)	0.009	6 (3.2)	0 (0.0)	6 (6.4)	0.013
Deep venous thrombosis	12 (1.1)	9 (0.9)	3 (3.1)	0.056	3 (1.6)	0 (0.0)	3 (3.2)	0.081
Lymphocysts	4 (0.4)	3 (0.3)	1 (1.0)	0.272	1 (0.5)	0 (0.0)	1 (1.0)	0.316
Unhealing wound	7 (0.7)	6 (0.6)	1 (1.0)	0.639	1 (0.5)	0 (0.0)	1 (1.0)	0.155
Others	4 (0.4)	2 (0.2)	2 (2.1)	0.005	2 (1.1)	0 (0.0)	2 (2.1)	0.005
Length of hospital stay (day)	14 (3-48)	14 (3-48)	15 (5-37)	0.001	14 (5-37)	14 (5-26)	15 (5-37)	0.001
Postoperative Length of hospital stay (day)	9 (0-46)	9 (0-46)	11 (2-32)	<0.001	10 (2-32)	9 (3-19)	11 (2-32)	0.001

Table3. COX regression analysis of DFS

Factor	Univariate COX analysis			Multivariate COX ranalysis		
	HR	95% CI	P	HR	95% CI	P
Comorbidities						
No	1	1		1	1	
Yes	10.0	1.211-81.456	0.032			
Omentectomy						
No	1	1		1	1	
Yes	10.7	2.540-45.273	0.001			
Cervical involvement						
No	1	1		1	1	
Yes	3.6	0.717-17.983	0.120	11.1	1.615-76.656	0.014
Lymph node involvement						
No	1	1		1	1	
Yes	94.9	18.617-483.892	<0.001	46.1	5.719-372.315	<0.001
Parametrium involvement						
No	1	1				
Yes	61.6	6.405-519.985	<0.001			
Type of hysterectomy						
Type A	1	1		1	1	
Type B/C	1.4	0.331-5.942	0.647	2.4	0.288-20.446	0.415

Funding : Taishan Scholar Youth Project of Shandong Province (grant number tsqn201812130) and the Research Leader Studio of Jinan (grant number 2019GXRC049)

Conflict of interests: None

Final publication Number: 554P